mRNA Cancer Vaccines and Therapeutics

mRNA Cancer Vaccines and Therapeutics Comprehensive Study by Type (Adeno Carcinomas, Mucinous Carcinomas, Adenosquamous Carcinomas), Application (Infectious Disease, Cancer, Others), End-users (Hospitals & Clinics, Ambulatory Surgical Centers, Research Institutes, Others) Players and Region - Global Market Outlook to 2027

mRNA Cancer Vaccines and Therapeutics Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is mRNA Cancer Vaccines and Therapeutics?
mRNA most cancers vaccines are a noticeably new category of vaccines, which mix the doable of mRNA to encode for nearly any protein with an extraordinary security profile and a bendy manufacturing process. The simplest use of mRNA vaccines in oncologic settings is the immunization of sufferers with mRNA vaccines encoding tumor-associated antigens (TAAs). This is exemplified with the aid of the RNActive® technology, which induces balanced humoral and cell immune responses in animal fashions and is presently evaluated in numerous medical trials for oncologic indications.

AttributesDetails
Study Period2017-2027
Base Year2021
UnitValue (USD Million)
Key Companies ProfiledModerna Therapeutics (United States), eTheRNA (Belgium), BioNTech (Germany), Cure Vac (Netherlands), In-Cell-Art (France), Translate Bio (United States), Tiba Biotechnology (United States), Argos Therapeutics (United States), Sangamo Therapeutics (United States) and Ethris (Germany)
CAGR%


The market study is broken down by Type (Adeno Carcinomas, Mucinous Carcinomas and Adenosquamous Carcinomas), by Application (Infectious Disease, Cancer and Others) and major geographies with country level break-up.

The market is seeing moderate market players, by seeing huge growth in this market the key leading vendors are highly focusing towards the production technologies, efficiency enhancement and product life. There is various growth opportunity in this market which is captured by leading players via tracking the ongoing process enhancement and huge invest in market growth strategies. Analysts at AMA Research estimates that Players from United States will contribute to the maximum growth of Global mRNA Cancer Vaccines and Therapeutics market throughout the predicted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Moderna Therapeutics (United States), eTheRNA (Belgium), BioNTech (Germany), Cure Vac (Netherlands), In-Cell-Art (France), Translate Bio (United States), Tiba Biotechnology (United States), Argos Therapeutics (United States), Sangamo Therapeutics (United States) and Ethris (Germany) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Bayer Group (Germany), Boehringer Ingelheim (Germany) and Intellia Therapeutics (United States).

Segmentation Overview
AdvanceMarketAnalytics has segmented the market of Global mRNA Cancer Vaccines and Therapeutics market by Type, Application and Region.

On the basis of geography, the market of mRNA Cancer Vaccines and Therapeutics has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by End-users, the sub-segment i.e. Hospitals & Clinics will boost the mRNA Cancer Vaccines and Therapeutics market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

In 2021, Bayer AG introduced the acquisition of Vividion Therapeutics, Inc. (Vividion), a US-headquartered biopharmaceutical organisation utilising novel discovery applied sciences to unencumber excessive value, historically undruggable objectives with precision therapeutics., and In 2022 Moderna introduced the improvement of mRNA vaccines for 15 diseases: Chikungunya virus, COVID-19, Crimean-Congo haemorrhagic fever, Dengue, Ebola virus disease, HIV, Malaria, Marburg virus disease, Lassa fever, Middle East respiratory syndrome coronavirus (MERS-CoV), Nipah and henipaviral diseases, Rift Valley fever, Severe fever with Thrombocytopenia syndrome, Tuberculosis and Zika.


Market Trend
  • Prophylactic vaccines
  • Therapeutic Vaccines Are Likely To Be a Niche Space for Mrna Products, But With Significant Commercial Potential Owing To the Size of the Patient

Market Drivers
  • Higher Efficiency of the Vaccine
  • Rising Prevalence of Infectious and Chronic Diseases, Such As HIV, Diabetes, Cancer, And Cardiovascular Diseases

Opportunities
  • Increasing Healthcare Expenditure

Restraints
  • Side Effects Possessed by the Vaccine
  • High Cost Associated with Vaccines

Challenges
  • Lack of Availability of Vaccines
  • Cancer Cells Suppress the Immune System
  • Cancer Cells Start from a Person's Own Healthy Cells


Key Target Audience
Biotechnology Companies, Pharmaceutical and Healthcare Companies, Consulting and Advisory Firms, Government and Policy Makers and Regulatory Authorities

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have the better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with purpose to understand company’s positioning regarding market value, volume and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders etc. and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and after getting appointee list; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey etc.

Report Objectives / Segmentation Covered

By Type
  • Adeno Carcinomas
  • Mucinous Carcinomas
  • Adenosquamous Carcinomas
By Application
  • Infectious Disease
  • Cancer
  • Others
By End-users
  • Hospitals & Clinics
  • Ambulatory Surgical Centers
  • Research Institutes
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Higher Efficiency of the Vaccine
      • 3.2.2. Rising Prevalence of Infectious and Chronic Diseases, Such As HIV, Diabetes, Cancer, And Cardiovascular Diseases
    • 3.3. Market Challenges
      • 3.3.1. Lack of Availability of Vaccines
      • 3.3.2. Cancer Cells Suppress the Immune System
      • 3.3.3. Cancer Cells Start from a Person's Own Healthy Cells
    • 3.4. Market Trends
      • 3.4.1. Prophylactic vaccines
      • 3.4.2. Therapeutic Vaccines Are Likely To Be a Niche Space for Mrna Products, But With Significant Commercial Potential Owing To the Size of the Patient
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global mRNA Cancer Vaccines and Therapeutics, by Type, Application, End-users and Region (value, volume and price ) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global mRNA Cancer Vaccines and Therapeutics (Value)
      • 5.2.1. Global mRNA Cancer Vaccines and Therapeutics by: Type (Value)
        • 5.2.1.1. Adeno Carcinomas
        • 5.2.1.2. Mucinous Carcinomas
        • 5.2.1.3. Adenosquamous Carcinomas
      • 5.2.2. Global mRNA Cancer Vaccines and Therapeutics by: Application (Value)
        • 5.2.2.1. Infectious Disease
        • 5.2.2.2. Cancer
        • 5.2.2.3. Others
      • 5.2.3. Global mRNA Cancer Vaccines and Therapeutics by: End-users (Value)
        • 5.2.3.1. Hospitals & Clinics
        • 5.2.3.2. Ambulatory Surgical Centers
        • 5.2.3.3. Research Institutes
        • 5.2.3.4. Others
      • 5.2.4. Global mRNA Cancer Vaccines and Therapeutics Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global mRNA Cancer Vaccines and Therapeutics (Volume)
      • 5.3.1. Global mRNA Cancer Vaccines and Therapeutics by: Type (Volume)
        • 5.3.1.1. Adeno Carcinomas
        • 5.3.1.2. Mucinous Carcinomas
        • 5.3.1.3. Adenosquamous Carcinomas
      • 5.3.2. Global mRNA Cancer Vaccines and Therapeutics by: Application (Volume)
        • 5.3.2.1. Infectious Disease
        • 5.3.2.2. Cancer
        • 5.3.2.3. Others
      • 5.3.3. Global mRNA Cancer Vaccines and Therapeutics by: End-users (Volume)
        • 5.3.3.1. Hospitals & Clinics
        • 5.3.3.2. Ambulatory Surgical Centers
        • 5.3.3.3. Research Institutes
        • 5.3.3.4. Others
      • 5.3.4. Global mRNA Cancer Vaccines and Therapeutics Region
        • 5.3.4.1. South America
          • 5.3.4.1.1. Brazil
          • 5.3.4.1.2. Argentina
          • 5.3.4.1.3. Rest of South America
        • 5.3.4.2. Asia Pacific
          • 5.3.4.2.1. China
          • 5.3.4.2.2. Japan
          • 5.3.4.2.3. India
          • 5.3.4.2.4. South Korea
          • 5.3.4.2.5. Taiwan
          • 5.3.4.2.6. Australia
          • 5.3.4.2.7. Rest of Asia-Pacific
        • 5.3.4.3. Europe
          • 5.3.4.3.1. Germany
          • 5.3.4.3.2. France
          • 5.3.4.3.3. Italy
          • 5.3.4.3.4. United Kingdom
          • 5.3.4.3.5. Netherlands
          • 5.3.4.3.6. Rest of Europe
        • 5.3.4.4. MEA
          • 5.3.4.4.1. Middle East
          • 5.3.4.4.2. Africa
        • 5.3.4.5. North America
          • 5.3.4.5.1. United States
          • 5.3.4.5.2. Canada
          • 5.3.4.5.3. Mexico
    • 5.4. Global mRNA Cancer Vaccines and Therapeutics (Price)
      • 5.4.1. Global mRNA Cancer Vaccines and Therapeutics by: Type (Price)
  • 6. mRNA Cancer Vaccines and Therapeutics: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Moderna Therapeutics (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. ETheRNA (Belgium)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. BioNTech (Germany)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Cure Vac (Netherlands)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. In-Cell-Art (France)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Translate Bio (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Tiba Biotechnology (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Argos Therapeutics (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Sangamo Therapeutics (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Ethris (Germany)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global mRNA Cancer Vaccines and Therapeutics Sale, by Type, Application, End-users and Region (value, volume and price ) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global mRNA Cancer Vaccines and Therapeutics (Value)
      • 7.2.1. Global mRNA Cancer Vaccines and Therapeutics by: Type (Value)
        • 7.2.1.1. Adeno Carcinomas
        • 7.2.1.2. Mucinous Carcinomas
        • 7.2.1.3. Adenosquamous Carcinomas
      • 7.2.2. Global mRNA Cancer Vaccines and Therapeutics by: Application (Value)
        • 7.2.2.1. Infectious Disease
        • 7.2.2.2. Cancer
        • 7.2.2.3. Others
      • 7.2.3. Global mRNA Cancer Vaccines and Therapeutics by: End-users (Value)
        • 7.2.3.1. Hospitals & Clinics
        • 7.2.3.2. Ambulatory Surgical Centers
        • 7.2.3.3. Research Institutes
        • 7.2.3.4. Others
      • 7.2.4. Global mRNA Cancer Vaccines and Therapeutics Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global mRNA Cancer Vaccines and Therapeutics (Volume)
      • 7.3.1. Global mRNA Cancer Vaccines and Therapeutics by: Type (Volume)
        • 7.3.1.1. Adeno Carcinomas
        • 7.3.1.2. Mucinous Carcinomas
        • 7.3.1.3. Adenosquamous Carcinomas
      • 7.3.2. Global mRNA Cancer Vaccines and Therapeutics by: Application (Volume)
        • 7.3.2.1. Infectious Disease
        • 7.3.2.2. Cancer
        • 7.3.2.3. Others
      • 7.3.3. Global mRNA Cancer Vaccines and Therapeutics by: End-users (Volume)
        • 7.3.3.1. Hospitals & Clinics
        • 7.3.3.2. Ambulatory Surgical Centers
        • 7.3.3.3. Research Institutes
        • 7.3.3.4. Others
      • 7.3.4. Global mRNA Cancer Vaccines and Therapeutics Region
        • 7.3.4.1. South America
          • 7.3.4.1.1. Brazil
          • 7.3.4.1.2. Argentina
          • 7.3.4.1.3. Rest of South America
        • 7.3.4.2. Asia Pacific
          • 7.3.4.2.1. China
          • 7.3.4.2.2. Japan
          • 7.3.4.2.3. India
          • 7.3.4.2.4. South Korea
          • 7.3.4.2.5. Taiwan
          • 7.3.4.2.6. Australia
          • 7.3.4.2.7. Rest of Asia-Pacific
        • 7.3.4.3. Europe
          • 7.3.4.3.1. Germany
          • 7.3.4.3.2. France
          • 7.3.4.3.3. Italy
          • 7.3.4.3.4. United Kingdom
          • 7.3.4.3.5. Netherlands
          • 7.3.4.3.6. Rest of Europe
        • 7.3.4.4. MEA
          • 7.3.4.4.1. Middle East
          • 7.3.4.4.2. Africa
        • 7.3.4.5. North America
          • 7.3.4.5.1. United States
          • 7.3.4.5.2. Canada
          • 7.3.4.5.3. Mexico
    • 7.4. Global mRNA Cancer Vaccines and Therapeutics (Price)
      • 7.4.1. Global mRNA Cancer Vaccines and Therapeutics by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. mRNA Cancer Vaccines and Therapeutics: by Type(USD Million)
  • Table 2. mRNA Cancer Vaccines and Therapeutics Adeno Carcinomas , by Region USD Million (2016-2021)
  • Table 3. mRNA Cancer Vaccines and Therapeutics Mucinous Carcinomas , by Region USD Million (2016-2021)
  • Table 4. mRNA Cancer Vaccines and Therapeutics Adenosquamous Carcinomas , by Region USD Million (2016-2021)
  • Table 5. mRNA Cancer Vaccines and Therapeutics: by Application(USD Million)
  • Table 6. mRNA Cancer Vaccines and Therapeutics Infectious Disease , by Region USD Million (2016-2021)
  • Table 7. mRNA Cancer Vaccines and Therapeutics Cancer , by Region USD Million (2016-2021)
  • Table 8. mRNA Cancer Vaccines and Therapeutics Others , by Region USD Million (2016-2021)
  • Table 9. mRNA Cancer Vaccines and Therapeutics: by End-users(USD Million)
  • Table 10. mRNA Cancer Vaccines and Therapeutics Hospitals & Clinics , by Region USD Million (2016-2021)
  • Table 11. mRNA Cancer Vaccines and Therapeutics Ambulatory Surgical Centers , by Region USD Million (2016-2021)
  • Table 12. mRNA Cancer Vaccines and Therapeutics Research Institutes , by Region USD Million (2016-2021)
  • Table 13. mRNA Cancer Vaccines and Therapeutics Others , by Region USD Million (2016-2021)
  • Table 14. South America mRNA Cancer Vaccines and Therapeutics, by Country USD Million (2016-2021)
  • Table 15. South America mRNA Cancer Vaccines and Therapeutics, by Type USD Million (2016-2021)
  • Table 16. South America mRNA Cancer Vaccines and Therapeutics, by Application USD Million (2016-2021)
  • Table 17. South America mRNA Cancer Vaccines and Therapeutics, by End-users USD Million (2016-2021)
  • Table 18. Brazil mRNA Cancer Vaccines and Therapeutics, by Type USD Million (2016-2021)
  • Table 19. Brazil mRNA Cancer Vaccines and Therapeutics, by Application USD Million (2016-2021)
  • Table 20. Brazil mRNA Cancer Vaccines and Therapeutics, by End-users USD Million (2016-2021)
  • Table 21. Argentina mRNA Cancer Vaccines and Therapeutics, by Type USD Million (2016-2021)
  • Table 22. Argentina mRNA Cancer Vaccines and Therapeutics, by Application USD Million (2016-2021)
  • Table 23. Argentina mRNA Cancer Vaccines and Therapeutics, by End-users USD Million (2016-2021)
  • Table 24. Rest of South America mRNA Cancer Vaccines and Therapeutics, by Type USD Million (2016-2021)
  • Table 25. Rest of South America mRNA Cancer Vaccines and Therapeutics, by Application USD Million (2016-2021)
  • Table 26. Rest of South America mRNA Cancer Vaccines and Therapeutics, by End-users USD Million (2016-2021)
  • Table 27. Asia Pacific mRNA Cancer Vaccines and Therapeutics, by Country USD Million (2016-2021)
  • Table 28. Asia Pacific mRNA Cancer Vaccines and Therapeutics, by Type USD Million (2016-2021)
  • Table 29. Asia Pacific mRNA Cancer Vaccines and Therapeutics, by Application USD Million (2016-2021)
  • Table 30. Asia Pacific mRNA Cancer Vaccines and Therapeutics, by End-users USD Million (2016-2021)
  • Table 31. China mRNA Cancer Vaccines and Therapeutics, by Type USD Million (2016-2021)
  • Table 32. China mRNA Cancer Vaccines and Therapeutics, by Application USD Million (2016-2021)
  • Table 33. China mRNA Cancer Vaccines and Therapeutics, by End-users USD Million (2016-2021)
  • Table 34. Japan mRNA Cancer Vaccines and Therapeutics, by Type USD Million (2016-2021)
  • Table 35. Japan mRNA Cancer Vaccines and Therapeutics, by Application USD Million (2016-2021)
  • Table 36. Japan mRNA Cancer Vaccines and Therapeutics, by End-users USD Million (2016-2021)
  • Table 37. India mRNA Cancer Vaccines and Therapeutics, by Type USD Million (2016-2021)
  • Table 38. India mRNA Cancer Vaccines and Therapeutics, by Application USD Million (2016-2021)
  • Table 39. India mRNA Cancer Vaccines and Therapeutics, by End-users USD Million (2016-2021)
  • Table 40. South Korea mRNA Cancer Vaccines and Therapeutics, by Type USD Million (2016-2021)
  • Table 41. South Korea mRNA Cancer Vaccines and Therapeutics, by Application USD Million (2016-2021)
  • Table 42. South Korea mRNA Cancer Vaccines and Therapeutics, by End-users USD Million (2016-2021)
  • Table 43. Taiwan mRNA Cancer Vaccines and Therapeutics, by Type USD Million (2016-2021)
  • Table 44. Taiwan mRNA Cancer Vaccines and Therapeutics, by Application USD Million (2016-2021)
  • Table 45. Taiwan mRNA Cancer Vaccines and Therapeutics, by End-users USD Million (2016-2021)
  • Table 46. Australia mRNA Cancer Vaccines and Therapeutics, by Type USD Million (2016-2021)
  • Table 47. Australia mRNA Cancer Vaccines and Therapeutics, by Application USD Million (2016-2021)
  • Table 48. Australia mRNA Cancer Vaccines and Therapeutics, by End-users USD Million (2016-2021)
  • Table 49. Rest of Asia-Pacific mRNA Cancer Vaccines and Therapeutics, by Type USD Million (2016-2021)
  • Table 50. Rest of Asia-Pacific mRNA Cancer Vaccines and Therapeutics, by Application USD Million (2016-2021)
  • Table 51. Rest of Asia-Pacific mRNA Cancer Vaccines and Therapeutics, by End-users USD Million (2016-2021)
  • Table 52. Europe mRNA Cancer Vaccines and Therapeutics, by Country USD Million (2016-2021)
  • Table 53. Europe mRNA Cancer Vaccines and Therapeutics, by Type USD Million (2016-2021)
  • Table 54. Europe mRNA Cancer Vaccines and Therapeutics, by Application USD Million (2016-2021)
  • Table 55. Europe mRNA Cancer Vaccines and Therapeutics, by End-users USD Million (2016-2021)
  • Table 56. Germany mRNA Cancer Vaccines and Therapeutics, by Type USD Million (2016-2021)
  • Table 57. Germany mRNA Cancer Vaccines and Therapeutics, by Application USD Million (2016-2021)
  • Table 58. Germany mRNA Cancer Vaccines and Therapeutics, by End-users USD Million (2016-2021)
  • Table 59. France mRNA Cancer Vaccines and Therapeutics, by Type USD Million (2016-2021)
  • Table 60. France mRNA Cancer Vaccines and Therapeutics, by Application USD Million (2016-2021)
  • Table 61. France mRNA Cancer Vaccines and Therapeutics, by End-users USD Million (2016-2021)
  • Table 62. Italy mRNA Cancer Vaccines and Therapeutics, by Type USD Million (2016-2021)
  • Table 63. Italy mRNA Cancer Vaccines and Therapeutics, by Application USD Million (2016-2021)
  • Table 64. Italy mRNA Cancer Vaccines and Therapeutics, by End-users USD Million (2016-2021)
  • Table 65. United Kingdom mRNA Cancer Vaccines and Therapeutics, by Type USD Million (2016-2021)
  • Table 66. United Kingdom mRNA Cancer Vaccines and Therapeutics, by Application USD Million (2016-2021)
  • Table 67. United Kingdom mRNA Cancer Vaccines and Therapeutics, by End-users USD Million (2016-2021)
  • Table 68. Netherlands mRNA Cancer Vaccines and Therapeutics, by Type USD Million (2016-2021)
  • Table 69. Netherlands mRNA Cancer Vaccines and Therapeutics, by Application USD Million (2016-2021)
  • Table 70. Netherlands mRNA Cancer Vaccines and Therapeutics, by End-users USD Million (2016-2021)
  • Table 71. Rest of Europe mRNA Cancer Vaccines and Therapeutics, by Type USD Million (2016-2021)
  • Table 72. Rest of Europe mRNA Cancer Vaccines and Therapeutics, by Application USD Million (2016-2021)
  • Table 73. Rest of Europe mRNA Cancer Vaccines and Therapeutics, by End-users USD Million (2016-2021)
  • Table 74. MEA mRNA Cancer Vaccines and Therapeutics, by Country USD Million (2016-2021)
  • Table 75. MEA mRNA Cancer Vaccines and Therapeutics, by Type USD Million (2016-2021)
  • Table 76. MEA mRNA Cancer Vaccines and Therapeutics, by Application USD Million (2016-2021)
  • Table 77. MEA mRNA Cancer Vaccines and Therapeutics, by End-users USD Million (2016-2021)
  • Table 78. Middle East mRNA Cancer Vaccines and Therapeutics, by Type USD Million (2016-2021)
  • Table 79. Middle East mRNA Cancer Vaccines and Therapeutics, by Application USD Million (2016-2021)
  • Table 80. Middle East mRNA Cancer Vaccines and Therapeutics, by End-users USD Million (2016-2021)
  • Table 81. Africa mRNA Cancer Vaccines and Therapeutics, by Type USD Million (2016-2021)
  • Table 82. Africa mRNA Cancer Vaccines and Therapeutics, by Application USD Million (2016-2021)
  • Table 83. Africa mRNA Cancer Vaccines and Therapeutics, by End-users USD Million (2016-2021)
  • Table 84. North America mRNA Cancer Vaccines and Therapeutics, by Country USD Million (2016-2021)
  • Table 85. North America mRNA Cancer Vaccines and Therapeutics, by Type USD Million (2016-2021)
  • Table 86. North America mRNA Cancer Vaccines and Therapeutics, by Application USD Million (2016-2021)
  • Table 87. North America mRNA Cancer Vaccines and Therapeutics, by End-users USD Million (2016-2021)
  • Table 88. United States mRNA Cancer Vaccines and Therapeutics, by Type USD Million (2016-2021)
  • Table 89. United States mRNA Cancer Vaccines and Therapeutics, by Application USD Million (2016-2021)
  • Table 90. United States mRNA Cancer Vaccines and Therapeutics, by End-users USD Million (2016-2021)
  • Table 91. Canada mRNA Cancer Vaccines and Therapeutics, by Type USD Million (2016-2021)
  • Table 92. Canada mRNA Cancer Vaccines and Therapeutics, by Application USD Million (2016-2021)
  • Table 93. Canada mRNA Cancer Vaccines and Therapeutics, by End-users USD Million (2016-2021)
  • Table 94. Mexico mRNA Cancer Vaccines and Therapeutics, by Type USD Million (2016-2021)
  • Table 95. Mexico mRNA Cancer Vaccines and Therapeutics, by Application USD Million (2016-2021)
  • Table 96. Mexico mRNA Cancer Vaccines and Therapeutics, by End-users USD Million (2016-2021)
  • Table 97. mRNA Cancer Vaccines and Therapeutics Sales: by Type(N)
  • Table 98. mRNA Cancer Vaccines and Therapeutics Sales Adeno Carcinomas , by Region N (2016-2021)
  • Table 99. mRNA Cancer Vaccines and Therapeutics Sales Mucinous Carcinomas , by Region N (2016-2021)
  • Table 100. mRNA Cancer Vaccines and Therapeutics Sales Adenosquamous Carcinomas , by Region N (2016-2021)
  • Table 101. mRNA Cancer Vaccines and Therapeutics Sales: by Application(N)
  • Table 102. mRNA Cancer Vaccines and Therapeutics Sales Infectious Disease , by Region N (2016-2021)
  • Table 103. mRNA Cancer Vaccines and Therapeutics Sales Cancer , by Region N (2016-2021)
  • Table 104. mRNA Cancer Vaccines and Therapeutics Sales Others , by Region N (2016-2021)
  • Table 105. mRNA Cancer Vaccines and Therapeutics Sales: by End-users(N)
  • Table 106. mRNA Cancer Vaccines and Therapeutics Sales Hospitals & Clinics , by Region N (2016-2021)
  • Table 107. mRNA Cancer Vaccines and Therapeutics Sales Ambulatory Surgical Centers , by Region N (2016-2021)
  • Table 108. mRNA Cancer Vaccines and Therapeutics Sales Research Institutes , by Region N (2016-2021)
  • Table 109. mRNA Cancer Vaccines and Therapeutics Sales Others , by Region N (2016-2021)
  • Table 110. South America mRNA Cancer Vaccines and Therapeutics Sales, by Country N (2016-2021)
  • Table 111. South America mRNA Cancer Vaccines and Therapeutics Sales, by Type N (2016-2021)
  • Table 112. South America mRNA Cancer Vaccines and Therapeutics Sales, by Application N (2016-2021)
  • Table 113. South America mRNA Cancer Vaccines and Therapeutics Sales, by End-users N (2016-2021)
  • Table 114. Brazil mRNA Cancer Vaccines and Therapeutics Sales, by Type N (2016-2021)
  • Table 115. Brazil mRNA Cancer Vaccines and Therapeutics Sales, by Application N (2016-2021)
  • Table 116. Brazil mRNA Cancer Vaccines and Therapeutics Sales, by End-users N (2016-2021)
  • Table 117. Argentina mRNA Cancer Vaccines and Therapeutics Sales, by Type N (2016-2021)
  • Table 118. Argentina mRNA Cancer Vaccines and Therapeutics Sales, by Application N (2016-2021)
  • Table 119. Argentina mRNA Cancer Vaccines and Therapeutics Sales, by End-users N (2016-2021)
  • Table 120. Rest of South America mRNA Cancer Vaccines and Therapeutics Sales, by Type N (2016-2021)
  • Table 121. Rest of South America mRNA Cancer Vaccines and Therapeutics Sales, by Application N (2016-2021)
  • Table 122. Rest of South America mRNA Cancer Vaccines and Therapeutics Sales, by End-users N (2016-2021)
  • Table 123. Asia Pacific mRNA Cancer Vaccines and Therapeutics Sales, by Country N (2016-2021)
  • Table 124. Asia Pacific mRNA Cancer Vaccines and Therapeutics Sales, by Type N (2016-2021)
  • Table 125. Asia Pacific mRNA Cancer Vaccines and Therapeutics Sales, by Application N (2016-2021)
  • Table 126. Asia Pacific mRNA Cancer Vaccines and Therapeutics Sales, by End-users N (2016-2021)
  • Table 127. China mRNA Cancer Vaccines and Therapeutics Sales, by Type N (2016-2021)
  • Table 128. China mRNA Cancer Vaccines and Therapeutics Sales, by Application N (2016-2021)
  • Table 129. China mRNA Cancer Vaccines and Therapeutics Sales, by End-users N (2016-2021)
  • Table 130. Japan mRNA Cancer Vaccines and Therapeutics Sales, by Type N (2016-2021)
  • Table 131. Japan mRNA Cancer Vaccines and Therapeutics Sales, by Application N (2016-2021)
  • Table 132. Japan mRNA Cancer Vaccines and Therapeutics Sales, by End-users N (2016-2021)
  • Table 133. India mRNA Cancer Vaccines and Therapeutics Sales, by Type N (2016-2021)
  • Table 134. India mRNA Cancer Vaccines and Therapeutics Sales, by Application N (2016-2021)
  • Table 135. India mRNA Cancer Vaccines and Therapeutics Sales, by End-users N (2016-2021)
  • Table 136. South Korea mRNA Cancer Vaccines and Therapeutics Sales, by Type N (2016-2021)
  • Table 137. South Korea mRNA Cancer Vaccines and Therapeutics Sales, by Application N (2016-2021)
  • Table 138. South Korea mRNA Cancer Vaccines and Therapeutics Sales, by End-users N (2016-2021)
  • Table 139. Taiwan mRNA Cancer Vaccines and Therapeutics Sales, by Type N (2016-2021)
  • Table 140. Taiwan mRNA Cancer Vaccines and Therapeutics Sales, by Application N (2016-2021)
  • Table 141. Taiwan mRNA Cancer Vaccines and Therapeutics Sales, by End-users N (2016-2021)
  • Table 142. Australia mRNA Cancer Vaccines and Therapeutics Sales, by Type N (2016-2021)
  • Table 143. Australia mRNA Cancer Vaccines and Therapeutics Sales, by Application N (2016-2021)
  • Table 144. Australia mRNA Cancer Vaccines and Therapeutics Sales, by End-users N (2016-2021)
  • Table 145. Rest of Asia-Pacific mRNA Cancer Vaccines and Therapeutics Sales, by Type N (2016-2021)
  • Table 146. Rest of Asia-Pacific mRNA Cancer Vaccines and Therapeutics Sales, by Application N (2016-2021)
  • Table 147. Rest of Asia-Pacific mRNA Cancer Vaccines and Therapeutics Sales, by End-users N (2016-2021)
  • Table 148. Europe mRNA Cancer Vaccines and Therapeutics Sales, by Country N (2016-2021)
  • Table 149. Europe mRNA Cancer Vaccines and Therapeutics Sales, by Type N (2016-2021)
  • Table 150. Europe mRNA Cancer Vaccines and Therapeutics Sales, by Application N (2016-2021)
  • Table 151. Europe mRNA Cancer Vaccines and Therapeutics Sales, by End-users N (2016-2021)
  • Table 152. Germany mRNA Cancer Vaccines and Therapeutics Sales, by Type N (2016-2021)
  • Table 153. Germany mRNA Cancer Vaccines and Therapeutics Sales, by Application N (2016-2021)
  • Table 154. Germany mRNA Cancer Vaccines and Therapeutics Sales, by End-users N (2016-2021)
  • Table 155. France mRNA Cancer Vaccines and Therapeutics Sales, by Type N (2016-2021)
  • Table 156. France mRNA Cancer Vaccines and Therapeutics Sales, by Application N (2016-2021)
  • Table 157. France mRNA Cancer Vaccines and Therapeutics Sales, by End-users N (2016-2021)
  • Table 158. Italy mRNA Cancer Vaccines and Therapeutics Sales, by Type N (2016-2021)
  • Table 159. Italy mRNA Cancer Vaccines and Therapeutics Sales, by Application N (2016-2021)
  • Table 160. Italy mRNA Cancer Vaccines and Therapeutics Sales, by End-users N (2016-2021)
  • Table 161. United Kingdom mRNA Cancer Vaccines and Therapeutics Sales, by Type N (2016-2021)
  • Table 162. United Kingdom mRNA Cancer Vaccines and Therapeutics Sales, by Application N (2016-2021)
  • Table 163. United Kingdom mRNA Cancer Vaccines and Therapeutics Sales, by End-users N (2016-2021)
  • Table 164. Netherlands mRNA Cancer Vaccines and Therapeutics Sales, by Type N (2016-2021)
  • Table 165. Netherlands mRNA Cancer Vaccines and Therapeutics Sales, by Application N (2016-2021)
  • Table 166. Netherlands mRNA Cancer Vaccines and Therapeutics Sales, by End-users N (2016-2021)
  • Table 167. Rest of Europe mRNA Cancer Vaccines and Therapeutics Sales, by Type N (2016-2021)
  • Table 168. Rest of Europe mRNA Cancer Vaccines and Therapeutics Sales, by Application N (2016-2021)
  • Table 169. Rest of Europe mRNA Cancer Vaccines and Therapeutics Sales, by End-users N (2016-2021)
  • Table 170. MEA mRNA Cancer Vaccines and Therapeutics Sales, by Country N (2016-2021)
  • Table 171. MEA mRNA Cancer Vaccines and Therapeutics Sales, by Type N (2016-2021)
  • Table 172. MEA mRNA Cancer Vaccines and Therapeutics Sales, by Application N (2016-2021)
  • Table 173. MEA mRNA Cancer Vaccines and Therapeutics Sales, by End-users N (2016-2021)
  • Table 174. Middle East mRNA Cancer Vaccines and Therapeutics Sales, by Type N (2016-2021)
  • Table 175. Middle East mRNA Cancer Vaccines and Therapeutics Sales, by Application N (2016-2021)
  • Table 176. Middle East mRNA Cancer Vaccines and Therapeutics Sales, by End-users N (2016-2021)
  • Table 177. Africa mRNA Cancer Vaccines and Therapeutics Sales, by Type N (2016-2021)
  • Table 178. Africa mRNA Cancer Vaccines and Therapeutics Sales, by Application N (2016-2021)
  • Table 179. Africa mRNA Cancer Vaccines and Therapeutics Sales, by End-users N (2016-2021)
  • Table 180. North America mRNA Cancer Vaccines and Therapeutics Sales, by Country N (2016-2021)
  • Table 181. North America mRNA Cancer Vaccines and Therapeutics Sales, by Type N (2016-2021)
  • Table 182. North America mRNA Cancer Vaccines and Therapeutics Sales, by Application N (2016-2021)
  • Table 183. North America mRNA Cancer Vaccines and Therapeutics Sales, by End-users N (2016-2021)
  • Table 184. United States mRNA Cancer Vaccines and Therapeutics Sales, by Type N (2016-2021)
  • Table 185. United States mRNA Cancer Vaccines and Therapeutics Sales, by Application N (2016-2021)
  • Table 186. United States mRNA Cancer Vaccines and Therapeutics Sales, by End-users N (2016-2021)
  • Table 187. Canada mRNA Cancer Vaccines and Therapeutics Sales, by Type N (2016-2021)
  • Table 188. Canada mRNA Cancer Vaccines and Therapeutics Sales, by Application N (2016-2021)
  • Table 189. Canada mRNA Cancer Vaccines and Therapeutics Sales, by End-users N (2016-2021)
  • Table 190. Mexico mRNA Cancer Vaccines and Therapeutics Sales, by Type N (2016-2021)
  • Table 191. Mexico mRNA Cancer Vaccines and Therapeutics Sales, by Application N (2016-2021)
  • Table 192. Mexico mRNA Cancer Vaccines and Therapeutics Sales, by End-users N (2016-2021)
  • Table 193. mRNA Cancer Vaccines and Therapeutics: by Type(USD/Units)
  • Table 194. Company Basic Information, Sales Area and Its Competitors
  • Table 195. Company Basic Information, Sales Area and Its Competitors
  • Table 196. Company Basic Information, Sales Area and Its Competitors
  • Table 197. Company Basic Information, Sales Area and Its Competitors
  • Table 198. Company Basic Information, Sales Area and Its Competitors
  • Table 199. Company Basic Information, Sales Area and Its Competitors
  • Table 200. Company Basic Information, Sales Area and Its Competitors
  • Table 201. Company Basic Information, Sales Area and Its Competitors
  • Table 202. Company Basic Information, Sales Area and Its Competitors
  • Table 203. Company Basic Information, Sales Area and Its Competitors
  • Table 204. mRNA Cancer Vaccines and Therapeutics: by Type(USD Million)
  • Table 205. mRNA Cancer Vaccines and Therapeutics Adeno Carcinomas , by Region USD Million (2022-2027)
  • Table 206. mRNA Cancer Vaccines and Therapeutics Mucinous Carcinomas , by Region USD Million (2022-2027)
  • Table 207. mRNA Cancer Vaccines and Therapeutics Adenosquamous Carcinomas , by Region USD Million (2022-2027)
  • Table 208. mRNA Cancer Vaccines and Therapeutics: by Application(USD Million)
  • Table 209. mRNA Cancer Vaccines and Therapeutics Infectious Disease , by Region USD Million (2022-2027)
  • Table 210. mRNA Cancer Vaccines and Therapeutics Cancer , by Region USD Million (2022-2027)
  • Table 211. mRNA Cancer Vaccines and Therapeutics Others , by Region USD Million (2022-2027)
  • Table 212. mRNA Cancer Vaccines and Therapeutics: by End-users(USD Million)
  • Table 213. mRNA Cancer Vaccines and Therapeutics Hospitals & Clinics , by Region USD Million (2022-2027)
  • Table 214. mRNA Cancer Vaccines and Therapeutics Ambulatory Surgical Centers , by Region USD Million (2022-2027)
  • Table 215. mRNA Cancer Vaccines and Therapeutics Research Institutes , by Region USD Million (2022-2027)
  • Table 216. mRNA Cancer Vaccines and Therapeutics Others , by Region USD Million (2022-2027)
  • Table 217. South America mRNA Cancer Vaccines and Therapeutics, by Country USD Million (2022-2027)
  • Table 218. South America mRNA Cancer Vaccines and Therapeutics, by Type USD Million (2022-2027)
  • Table 219. South America mRNA Cancer Vaccines and Therapeutics, by Application USD Million (2022-2027)
  • Table 220. South America mRNA Cancer Vaccines and Therapeutics, by End-users USD Million (2022-2027)
  • Table 221. Brazil mRNA Cancer Vaccines and Therapeutics, by Type USD Million (2022-2027)
  • Table 222. Brazil mRNA Cancer Vaccines and Therapeutics, by Application USD Million (2022-2027)
  • Table 223. Brazil mRNA Cancer Vaccines and Therapeutics, by End-users USD Million (2022-2027)
  • Table 224. Argentina mRNA Cancer Vaccines and Therapeutics, by Type USD Million (2022-2027)
  • Table 225. Argentina mRNA Cancer Vaccines and Therapeutics, by Application USD Million (2022-2027)
  • Table 226. Argentina mRNA Cancer Vaccines and Therapeutics, by End-users USD Million (2022-2027)
  • Table 227. Rest of South America mRNA Cancer Vaccines and Therapeutics, by Type USD Million (2022-2027)
  • Table 228. Rest of South America mRNA Cancer Vaccines and Therapeutics, by Application USD Million (2022-2027)
  • Table 229. Rest of South America mRNA Cancer Vaccines and Therapeutics, by End-users USD Million (2022-2027)
  • Table 230. Asia Pacific mRNA Cancer Vaccines and Therapeutics, by Country USD Million (2022-2027)
  • Table 231. Asia Pacific mRNA Cancer Vaccines and Therapeutics, by Type USD Million (2022-2027)
  • Table 232. Asia Pacific mRNA Cancer Vaccines and Therapeutics, by Application USD Million (2022-2027)
  • Table 233. Asia Pacific mRNA Cancer Vaccines and Therapeutics, by End-users USD Million (2022-2027)
  • Table 234. China mRNA Cancer Vaccines and Therapeutics, by Type USD Million (2022-2027)
  • Table 235. China mRNA Cancer Vaccines and Therapeutics, by Application USD Million (2022-2027)
  • Table 236. China mRNA Cancer Vaccines and Therapeutics, by End-users USD Million (2022-2027)
  • Table 237. Japan mRNA Cancer Vaccines and Therapeutics, by Type USD Million (2022-2027)
  • Table 238. Japan mRNA Cancer Vaccines and Therapeutics, by Application USD Million (2022-2027)
  • Table 239. Japan mRNA Cancer Vaccines and Therapeutics, by End-users USD Million (2022-2027)
  • Table 240. India mRNA Cancer Vaccines and Therapeutics, by Type USD Million (2022-2027)
  • Table 241. India mRNA Cancer Vaccines and Therapeutics, by Application USD Million (2022-2027)
  • Table 242. India mRNA Cancer Vaccines and Therapeutics, by End-users USD Million (2022-2027)
  • Table 243. South Korea mRNA Cancer Vaccines and Therapeutics, by Type USD Million (2022-2027)
  • Table 244. South Korea mRNA Cancer Vaccines and Therapeutics, by Application USD Million (2022-2027)
  • Table 245. South Korea mRNA Cancer Vaccines and Therapeutics, by End-users USD Million (2022-2027)
  • Table 246. Taiwan mRNA Cancer Vaccines and Therapeutics, by Type USD Million (2022-2027)
  • Table 247. Taiwan mRNA Cancer Vaccines and Therapeutics, by Application USD Million (2022-2027)
  • Table 248. Taiwan mRNA Cancer Vaccines and Therapeutics, by End-users USD Million (2022-2027)
  • Table 249. Australia mRNA Cancer Vaccines and Therapeutics, by Type USD Million (2022-2027)
  • Table 250. Australia mRNA Cancer Vaccines and Therapeutics, by Application USD Million (2022-2027)
  • Table 251. Australia mRNA Cancer Vaccines and Therapeutics, by End-users USD Million (2022-2027)
  • Table 252. Rest of Asia-Pacific mRNA Cancer Vaccines and Therapeutics, by Type USD Million (2022-2027)
  • Table 253. Rest of Asia-Pacific mRNA Cancer Vaccines and Therapeutics, by Application USD Million (2022-2027)
  • Table 254. Rest of Asia-Pacific mRNA Cancer Vaccines and Therapeutics, by End-users USD Million (2022-2027)
  • Table 255. Europe mRNA Cancer Vaccines and Therapeutics, by Country USD Million (2022-2027)
  • Table 256. Europe mRNA Cancer Vaccines and Therapeutics, by Type USD Million (2022-2027)
  • Table 257. Europe mRNA Cancer Vaccines and Therapeutics, by Application USD Million (2022-2027)
  • Table 258. Europe mRNA Cancer Vaccines and Therapeutics, by End-users USD Million (2022-2027)
  • Table 259. Germany mRNA Cancer Vaccines and Therapeutics, by Type USD Million (2022-2027)
  • Table 260. Germany mRNA Cancer Vaccines and Therapeutics, by Application USD Million (2022-2027)
  • Table 261. Germany mRNA Cancer Vaccines and Therapeutics, by End-users USD Million (2022-2027)
  • Table 262. France mRNA Cancer Vaccines and Therapeutics, by Type USD Million (2022-2027)
  • Table 263. France mRNA Cancer Vaccines and Therapeutics, by Application USD Million (2022-2027)
  • Table 264. France mRNA Cancer Vaccines and Therapeutics, by End-users USD Million (2022-2027)
  • Table 265. Italy mRNA Cancer Vaccines and Therapeutics, by Type USD Million (2022-2027)
  • Table 266. Italy mRNA Cancer Vaccines and Therapeutics, by Application USD Million (2022-2027)
  • Table 267. Italy mRNA Cancer Vaccines and Therapeutics, by End-users USD Million (2022-2027)
  • Table 268. United Kingdom mRNA Cancer Vaccines and Therapeutics, by Type USD Million (2022-2027)
  • Table 269. United Kingdom mRNA Cancer Vaccines and Therapeutics, by Application USD Million (2022-2027)
  • Table 270. United Kingdom mRNA Cancer Vaccines and Therapeutics, by End-users USD Million (2022-2027)
  • Table 271. Netherlands mRNA Cancer Vaccines and Therapeutics, by Type USD Million (2022-2027)
  • Table 272. Netherlands mRNA Cancer Vaccines and Therapeutics, by Application USD Million (2022-2027)
  • Table 273. Netherlands mRNA Cancer Vaccines and Therapeutics, by End-users USD Million (2022-2027)
  • Table 274. Rest of Europe mRNA Cancer Vaccines and Therapeutics, by Type USD Million (2022-2027)
  • Table 275. Rest of Europe mRNA Cancer Vaccines and Therapeutics, by Application USD Million (2022-2027)
  • Table 276. Rest of Europe mRNA Cancer Vaccines and Therapeutics, by End-users USD Million (2022-2027)
  • Table 277. MEA mRNA Cancer Vaccines and Therapeutics, by Country USD Million (2022-2027)
  • Table 278. MEA mRNA Cancer Vaccines and Therapeutics, by Type USD Million (2022-2027)
  • Table 279. MEA mRNA Cancer Vaccines and Therapeutics, by Application USD Million (2022-2027)
  • Table 280. MEA mRNA Cancer Vaccines and Therapeutics, by End-users USD Million (2022-2027)
  • Table 281. Middle East mRNA Cancer Vaccines and Therapeutics, by Type USD Million (2022-2027)
  • Table 282. Middle East mRNA Cancer Vaccines and Therapeutics, by Application USD Million (2022-2027)
  • Table 283. Middle East mRNA Cancer Vaccines and Therapeutics, by End-users USD Million (2022-2027)
  • Table 284. Africa mRNA Cancer Vaccines and Therapeutics, by Type USD Million (2022-2027)
  • Table 285. Africa mRNA Cancer Vaccines and Therapeutics, by Application USD Million (2022-2027)
  • Table 286. Africa mRNA Cancer Vaccines and Therapeutics, by End-users USD Million (2022-2027)
  • Table 287. North America mRNA Cancer Vaccines and Therapeutics, by Country USD Million (2022-2027)
  • Table 288. North America mRNA Cancer Vaccines and Therapeutics, by Type USD Million (2022-2027)
  • Table 289. North America mRNA Cancer Vaccines and Therapeutics, by Application USD Million (2022-2027)
  • Table 290. North America mRNA Cancer Vaccines and Therapeutics, by End-users USD Million (2022-2027)
  • Table 291. United States mRNA Cancer Vaccines and Therapeutics, by Type USD Million (2022-2027)
  • Table 292. United States mRNA Cancer Vaccines and Therapeutics, by Application USD Million (2022-2027)
  • Table 293. United States mRNA Cancer Vaccines and Therapeutics, by End-users USD Million (2022-2027)
  • Table 294. Canada mRNA Cancer Vaccines and Therapeutics, by Type USD Million (2022-2027)
  • Table 295. Canada mRNA Cancer Vaccines and Therapeutics, by Application USD Million (2022-2027)
  • Table 296. Canada mRNA Cancer Vaccines and Therapeutics, by End-users USD Million (2022-2027)
  • Table 297. Mexico mRNA Cancer Vaccines and Therapeutics, by Type USD Million (2022-2027)
  • Table 298. Mexico mRNA Cancer Vaccines and Therapeutics, by Application USD Million (2022-2027)
  • Table 299. Mexico mRNA Cancer Vaccines and Therapeutics, by End-users USD Million (2022-2027)
  • Table 300. mRNA Cancer Vaccines and Therapeutics Sales: by Type(N)
  • Table 301. mRNA Cancer Vaccines and Therapeutics Sales Adeno Carcinomas , by Region N (2022-2027)
  • Table 302. mRNA Cancer Vaccines and Therapeutics Sales Mucinous Carcinomas , by Region N (2022-2027)
  • Table 303. mRNA Cancer Vaccines and Therapeutics Sales Adenosquamous Carcinomas , by Region N (2022-2027)
  • Table 304. mRNA Cancer Vaccines and Therapeutics Sales: by Application(N)
  • Table 305. mRNA Cancer Vaccines and Therapeutics Sales Infectious Disease , by Region N (2022-2027)
  • Table 306. mRNA Cancer Vaccines and Therapeutics Sales Cancer , by Region N (2022-2027)
  • Table 307. mRNA Cancer Vaccines and Therapeutics Sales Others , by Region N (2022-2027)
  • Table 308. mRNA Cancer Vaccines and Therapeutics Sales: by End-users(N)
  • Table 309. mRNA Cancer Vaccines and Therapeutics Sales Hospitals & Clinics , by Region N (2022-2027)
  • Table 310. mRNA Cancer Vaccines and Therapeutics Sales Ambulatory Surgical Centers , by Region N (2022-2027)
  • Table 311. mRNA Cancer Vaccines and Therapeutics Sales Research Institutes , by Region N (2022-2027)
  • Table 312. mRNA Cancer Vaccines and Therapeutics Sales Others , by Region N (2022-2027)
  • Table 313. South America mRNA Cancer Vaccines and Therapeutics Sales, by Country N (2022-2027)
  • Table 314. South America mRNA Cancer Vaccines and Therapeutics Sales, by Type N (2022-2027)
  • Table 315. South America mRNA Cancer Vaccines and Therapeutics Sales, by Application N (2022-2027)
  • Table 316. South America mRNA Cancer Vaccines and Therapeutics Sales, by End-users N (2022-2027)
  • Table 317. Brazil mRNA Cancer Vaccines and Therapeutics Sales, by Type N (2022-2027)
  • Table 318. Brazil mRNA Cancer Vaccines and Therapeutics Sales, by Application N (2022-2027)
  • Table 319. Brazil mRNA Cancer Vaccines and Therapeutics Sales, by End-users N (2022-2027)
  • Table 320. Argentina mRNA Cancer Vaccines and Therapeutics Sales, by Type N (2022-2027)
  • Table 321. Argentina mRNA Cancer Vaccines and Therapeutics Sales, by Application N (2022-2027)
  • Table 322. Argentina mRNA Cancer Vaccines and Therapeutics Sales, by End-users N (2022-2027)
  • Table 323. Rest of South America mRNA Cancer Vaccines and Therapeutics Sales, by Type N (2022-2027)
  • Table 324. Rest of South America mRNA Cancer Vaccines and Therapeutics Sales, by Application N (2022-2027)
  • Table 325. Rest of South America mRNA Cancer Vaccines and Therapeutics Sales, by End-users N (2022-2027)
  • Table 326. Asia Pacific mRNA Cancer Vaccines and Therapeutics Sales, by Country N (2022-2027)
  • Table 327. Asia Pacific mRNA Cancer Vaccines and Therapeutics Sales, by Type N (2022-2027)
  • Table 328. Asia Pacific mRNA Cancer Vaccines and Therapeutics Sales, by Application N (2022-2027)
  • Table 329. Asia Pacific mRNA Cancer Vaccines and Therapeutics Sales, by End-users N (2022-2027)
  • Table 330. China mRNA Cancer Vaccines and Therapeutics Sales, by Type N (2022-2027)
  • Table 331. China mRNA Cancer Vaccines and Therapeutics Sales, by Application N (2022-2027)
  • Table 332. China mRNA Cancer Vaccines and Therapeutics Sales, by End-users N (2022-2027)
  • Table 333. Japan mRNA Cancer Vaccines and Therapeutics Sales, by Type N (2022-2027)
  • Table 334. Japan mRNA Cancer Vaccines and Therapeutics Sales, by Application N (2022-2027)
  • Table 335. Japan mRNA Cancer Vaccines and Therapeutics Sales, by End-users N (2022-2027)
  • Table 336. India mRNA Cancer Vaccines and Therapeutics Sales, by Type N (2022-2027)
  • Table 337. India mRNA Cancer Vaccines and Therapeutics Sales, by Application N (2022-2027)
  • Table 338. India mRNA Cancer Vaccines and Therapeutics Sales, by End-users N (2022-2027)
  • Table 339. South Korea mRNA Cancer Vaccines and Therapeutics Sales, by Type N (2022-2027)
  • Table 340. South Korea mRNA Cancer Vaccines and Therapeutics Sales, by Application N (2022-2027)
  • Table 341. South Korea mRNA Cancer Vaccines and Therapeutics Sales, by End-users N (2022-2027)
  • Table 342. Taiwan mRNA Cancer Vaccines and Therapeutics Sales, by Type N (2022-2027)
  • Table 343. Taiwan mRNA Cancer Vaccines and Therapeutics Sales, by Application N (2022-2027)
  • Table 344. Taiwan mRNA Cancer Vaccines and Therapeutics Sales, by End-users N (2022-2027)
  • Table 345. Australia mRNA Cancer Vaccines and Therapeutics Sales, by Type N (2022-2027)
  • Table 346. Australia mRNA Cancer Vaccines and Therapeutics Sales, by Application N (2022-2027)
  • Table 347. Australia mRNA Cancer Vaccines and Therapeutics Sales, by End-users N (2022-2027)
  • Table 348. Rest of Asia-Pacific mRNA Cancer Vaccines and Therapeutics Sales, by Type N (2022-2027)
  • Table 349. Rest of Asia-Pacific mRNA Cancer Vaccines and Therapeutics Sales, by Application N (2022-2027)
  • Table 350. Rest of Asia-Pacific mRNA Cancer Vaccines and Therapeutics Sales, by End-users N (2022-2027)
  • Table 351. Europe mRNA Cancer Vaccines and Therapeutics Sales, by Country N (2022-2027)
  • Table 352. Europe mRNA Cancer Vaccines and Therapeutics Sales, by Type N (2022-2027)
  • Table 353. Europe mRNA Cancer Vaccines and Therapeutics Sales, by Application N (2022-2027)
  • Table 354. Europe mRNA Cancer Vaccines and Therapeutics Sales, by End-users N (2022-2027)
  • Table 355. Germany mRNA Cancer Vaccines and Therapeutics Sales, by Type N (2022-2027)
  • Table 356. Germany mRNA Cancer Vaccines and Therapeutics Sales, by Application N (2022-2027)
  • Table 357. Germany mRNA Cancer Vaccines and Therapeutics Sales, by End-users N (2022-2027)
  • Table 358. France mRNA Cancer Vaccines and Therapeutics Sales, by Type N (2022-2027)
  • Table 359. France mRNA Cancer Vaccines and Therapeutics Sales, by Application N (2022-2027)
  • Table 360. France mRNA Cancer Vaccines and Therapeutics Sales, by End-users N (2022-2027)
  • Table 361. Italy mRNA Cancer Vaccines and Therapeutics Sales, by Type N (2022-2027)
  • Table 362. Italy mRNA Cancer Vaccines and Therapeutics Sales, by Application N (2022-2027)
  • Table 363. Italy mRNA Cancer Vaccines and Therapeutics Sales, by End-users N (2022-2027)
  • Table 364. United Kingdom mRNA Cancer Vaccines and Therapeutics Sales, by Type N (2022-2027)
  • Table 365. United Kingdom mRNA Cancer Vaccines and Therapeutics Sales, by Application N (2022-2027)
  • Table 366. United Kingdom mRNA Cancer Vaccines and Therapeutics Sales, by End-users N (2022-2027)
  • Table 367. Netherlands mRNA Cancer Vaccines and Therapeutics Sales, by Type N (2022-2027)
  • Table 368. Netherlands mRNA Cancer Vaccines and Therapeutics Sales, by Application N (2022-2027)
  • Table 369. Netherlands mRNA Cancer Vaccines and Therapeutics Sales, by End-users N (2022-2027)
  • Table 370. Rest of Europe mRNA Cancer Vaccines and Therapeutics Sales, by Type N (2022-2027)
  • Table 371. Rest of Europe mRNA Cancer Vaccines and Therapeutics Sales, by Application N (2022-2027)
  • Table 372. Rest of Europe mRNA Cancer Vaccines and Therapeutics Sales, by End-users N (2022-2027)
  • Table 373. MEA mRNA Cancer Vaccines and Therapeutics Sales, by Country N (2022-2027)
  • Table 374. MEA mRNA Cancer Vaccines and Therapeutics Sales, by Type N (2022-2027)
  • Table 375. MEA mRNA Cancer Vaccines and Therapeutics Sales, by Application N (2022-2027)
  • Table 376. MEA mRNA Cancer Vaccines and Therapeutics Sales, by End-users N (2022-2027)
  • Table 377. Middle East mRNA Cancer Vaccines and Therapeutics Sales, by Type N (2022-2027)
  • Table 378. Middle East mRNA Cancer Vaccines and Therapeutics Sales, by Application N (2022-2027)
  • Table 379. Middle East mRNA Cancer Vaccines and Therapeutics Sales, by End-users N (2022-2027)
  • Table 380. Africa mRNA Cancer Vaccines and Therapeutics Sales, by Type N (2022-2027)
  • Table 381. Africa mRNA Cancer Vaccines and Therapeutics Sales, by Application N (2022-2027)
  • Table 382. Africa mRNA Cancer Vaccines and Therapeutics Sales, by End-users N (2022-2027)
  • Table 383. North America mRNA Cancer Vaccines and Therapeutics Sales, by Country N (2022-2027)
  • Table 384. North America mRNA Cancer Vaccines and Therapeutics Sales, by Type N (2022-2027)
  • Table 385. North America mRNA Cancer Vaccines and Therapeutics Sales, by Application N (2022-2027)
  • Table 386. North America mRNA Cancer Vaccines and Therapeutics Sales, by End-users N (2022-2027)
  • Table 387. United States mRNA Cancer Vaccines and Therapeutics Sales, by Type N (2022-2027)
  • Table 388. United States mRNA Cancer Vaccines and Therapeutics Sales, by Application N (2022-2027)
  • Table 389. United States mRNA Cancer Vaccines and Therapeutics Sales, by End-users N (2022-2027)
  • Table 390. Canada mRNA Cancer Vaccines and Therapeutics Sales, by Type N (2022-2027)
  • Table 391. Canada mRNA Cancer Vaccines and Therapeutics Sales, by Application N (2022-2027)
  • Table 392. Canada mRNA Cancer Vaccines and Therapeutics Sales, by End-users N (2022-2027)
  • Table 393. Mexico mRNA Cancer Vaccines and Therapeutics Sales, by Type N (2022-2027)
  • Table 394. Mexico mRNA Cancer Vaccines and Therapeutics Sales, by Application N (2022-2027)
  • Table 395. Mexico mRNA Cancer Vaccines and Therapeutics Sales, by End-users N (2022-2027)
  • Table 396. mRNA Cancer Vaccines and Therapeutics: by Type(USD/Units)
  • Table 397. Research Programs/Design for This Report
  • Table 398. Key Data Information from Secondary Sources
  • Table 399. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global mRNA Cancer Vaccines and Therapeutics: by Type USD Million (2016-2021)
  • Figure 5. Global mRNA Cancer Vaccines and Therapeutics: by Application USD Million (2016-2021)
  • Figure 6. Global mRNA Cancer Vaccines and Therapeutics: by End-users USD Million (2016-2021)
  • Figure 7. South America mRNA Cancer Vaccines and Therapeutics Share (%), by Country
  • Figure 8. Asia Pacific mRNA Cancer Vaccines and Therapeutics Share (%), by Country
  • Figure 9. Europe mRNA Cancer Vaccines and Therapeutics Share (%), by Country
  • Figure 10. MEA mRNA Cancer Vaccines and Therapeutics Share (%), by Country
  • Figure 11. North America mRNA Cancer Vaccines and Therapeutics Share (%), by Country
  • Figure 12. Global mRNA Cancer Vaccines and Therapeutics: by Type N (2016-2021)
  • Figure 13. Global mRNA Cancer Vaccines and Therapeutics: by Application N (2016-2021)
  • Figure 14. Global mRNA Cancer Vaccines and Therapeutics: by End-users N (2016-2021)
  • Figure 15. South America mRNA Cancer Vaccines and Therapeutics Share (%), by Country
  • Figure 16. Asia Pacific mRNA Cancer Vaccines and Therapeutics Share (%), by Country
  • Figure 17. Europe mRNA Cancer Vaccines and Therapeutics Share (%), by Country
  • Figure 18. MEA mRNA Cancer Vaccines and Therapeutics Share (%), by Country
  • Figure 19. North America mRNA Cancer Vaccines and Therapeutics Share (%), by Country
  • Figure 20. Global mRNA Cancer Vaccines and Therapeutics: by Type USD/Units (2016-2021)
  • Figure 21. Global mRNA Cancer Vaccines and Therapeutics share by Players 2021 (%)
  • Figure 22. Global mRNA Cancer Vaccines and Therapeutics share by Players (Top 3) 2021(%)
  • Figure 23. Global mRNA Cancer Vaccines and Therapeutics share by Players (Top 5) 2021(%)
  • Figure 24. BCG Matrix for key Companies
  • Figure 25. Moderna Therapeutics (United States) Revenue, Net Income and Gross profit
  • Figure 26. Moderna Therapeutics (United States) Revenue: by Geography 2021
  • Figure 27. ETheRNA (Belgium) Revenue, Net Income and Gross profit
  • Figure 28. ETheRNA (Belgium) Revenue: by Geography 2021
  • Figure 29. BioNTech (Germany) Revenue, Net Income and Gross profit
  • Figure 30. BioNTech (Germany) Revenue: by Geography 2021
  • Figure 31. Cure Vac (Netherlands) Revenue, Net Income and Gross profit
  • Figure 32. Cure Vac (Netherlands) Revenue: by Geography 2021
  • Figure 33. In-Cell-Art (France) Revenue, Net Income and Gross profit
  • Figure 34. In-Cell-Art (France) Revenue: by Geography 2021
  • Figure 35. Translate Bio (United States) Revenue, Net Income and Gross profit
  • Figure 36. Translate Bio (United States) Revenue: by Geography 2021
  • Figure 37. Tiba Biotechnology (United States) Revenue, Net Income and Gross profit
  • Figure 38. Tiba Biotechnology (United States) Revenue: by Geography 2021
  • Figure 39. Argos Therapeutics (United States) Revenue, Net Income and Gross profit
  • Figure 40. Argos Therapeutics (United States) Revenue: by Geography 2021
  • Figure 41. Sangamo Therapeutics (United States) Revenue, Net Income and Gross profit
  • Figure 42. Sangamo Therapeutics (United States) Revenue: by Geography 2021
  • Figure 43. Ethris (Germany) Revenue, Net Income and Gross profit
  • Figure 44. Ethris (Germany) Revenue: by Geography 2021
  • Figure 45. Global mRNA Cancer Vaccines and Therapeutics: by Type USD Million (2022-2027)
  • Figure 46. Global mRNA Cancer Vaccines and Therapeutics: by Application USD Million (2022-2027)
  • Figure 47. Global mRNA Cancer Vaccines and Therapeutics: by End-users USD Million (2022-2027)
  • Figure 48. South America mRNA Cancer Vaccines and Therapeutics Share (%), by Country
  • Figure 49. Asia Pacific mRNA Cancer Vaccines and Therapeutics Share (%), by Country
  • Figure 50. Europe mRNA Cancer Vaccines and Therapeutics Share (%), by Country
  • Figure 51. MEA mRNA Cancer Vaccines and Therapeutics Share (%), by Country
  • Figure 52. North America mRNA Cancer Vaccines and Therapeutics Share (%), by Country
  • Figure 53. Global mRNA Cancer Vaccines and Therapeutics: by Type N (2022-2027)
  • Figure 54. Global mRNA Cancer Vaccines and Therapeutics: by Application N (2022-2027)
  • Figure 55. Global mRNA Cancer Vaccines and Therapeutics: by End-users N (2022-2027)
  • Figure 56. South America mRNA Cancer Vaccines and Therapeutics Share (%), by Country
  • Figure 57. Asia Pacific mRNA Cancer Vaccines and Therapeutics Share (%), by Country
  • Figure 58. Europe mRNA Cancer Vaccines and Therapeutics Share (%), by Country
  • Figure 59. MEA mRNA Cancer Vaccines and Therapeutics Share (%), by Country
  • Figure 60. North America mRNA Cancer Vaccines and Therapeutics Share (%), by Country
  • Figure 61. Global mRNA Cancer Vaccines and Therapeutics: by Type USD/Units (2022-2027)
List of companies from research coverage that are profiled in the study
  • Moderna Therapeutics (United States)
  • eTheRNA (Belgium)
  • BioNTech (Germany)
  • Cure Vac (Netherlands)
  • In-Cell-Art (France)
  • Translate Bio (United States)
  • Tiba Biotechnology (United States)
  • Argos Therapeutics (United States)
  • Sangamo Therapeutics (United States)
  • Ethris (Germany)
Additional players considered in the study are as follows:
Bayer Group (Germany) , Boehringer Ingelheim (Germany) , Intellia Therapeutics (United States)
Select User Access Type

Key Highlights of Report


Apr 2022 243 Pages 78 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
mRNA Cancer Vaccines and Therapeutics Quantitative research analysis
mRNA Cancer Vaccines and Therapeutics Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Moderna Therapeutics (United States), eTheRNA (Belgium), BioNTech (Germany), Cure Vac (Netherlands), In-Cell-Art (France), Translate Bio (United States), Tiba Biotechnology (United States), Argos Therapeutics (United States), Sangamo Therapeutics (United States) and Ethris (Germany) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
Analysts at AMA estimates mRNA Cancer Vaccines and Therapeutics Market to reach USD Million by 2027.

Know More About mRNA Cancer Vaccines and Therapeutics Report?

Have a Query? Click Here

Other Related Reports

Quercetin Dihydrate Comprehensive Study by Application (Atherosclerosis, Chronic Infections, Cosmetics, Nutraceuticals, Allergy & Inflammation, Others), Form (Powder, Solution), Distribution Channel ...
$ 3450
Calcium Supplement for Pets Comprehensive Study by Type (Tablets, Gel Cap, Powder, Liquid), Application (Dogs, Cats, Others), Distribution Channel (Online, Offline) Players and Region - Global Market...
$ 3800
Enoxaparin Comprehensive Study by Application (Infectious Diseases, Gynecology, Cancer, Diabetes, Cardiology, Osteoporosis, Others), Age Group (Adults, Children (2 months to 18 yr), Infants (1 to 2 m...
$ 3450
Famotidine Injection Comprehensive Study by Type (Premixed Solution, Concentrated Solution), Application (Ulcers, Gastroesophageal Reflux Disease, Zollinger-Ellison Syndrome, Others), Components (L-a...
$ 3750
Dog and Cat Calcium Tablet Comprehensive Study by Type (Plant Source, Systhesis), Application (Dogs, Cats), Distribution Channel (Online, Offline, Special Store, Others), Ingredients (Calcium, Vitami...
$ 3800
Finasteride Tablet Comprehensive Study by Type (1mg Tablet, 5mg Tablet), Application (Male Pattern Baldness, Benign Prostatic Hyperplasia, Others) Players and Region - Global Market Outlook to 2025
$ 3500